Quick Answer
TEVA PHARMACEUTICAL INDUSTRIES LTD reported Revenue (ASC 606) of $17.26 billion for fiscal year 2025.
TEVA PHARMACEUTICAL INDUSTRIES LTD Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $17.26B | +4.3% |
| 2024 | $16.54B | +4.4% |
| 2023 | $15.85B | +6.2% |
| 2022 | $14.93B | -6.0% |
| 2021 | $15.88B | -4.7% |
| 2020 | $16.66B | -1.4% |
| 2019 | $16.89B | -7.6% |
| 2018 | $18.27B | -16.4% |
| 2017 | $21.85B | -0.2% |
| 2016 | $21.90B | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.48B | +3.4% | +7.3% |
| June 30, 2025 | $4.18B | +0.3% | +7.3% |
| March 31, 2025 | $3.89B | +1.9% | -10.2% |
| September 30, 2024 | $4.33B | +12.5% | +4.0% |
| June 30, 2024 | $4.16B | +7.4% | +9.0% |
| March 31, 2024 | $3.82B | +4.3% | -0.8% |
| September 30, 2023 | $3.85B | +7.1% | -0.7% |
| June 30, 2023 | $3.88B | +2.4% | +5.9% |
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +4.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, TEVA PHARMACEUTICAL INDUSTRIES LTD’s revenue (asc 606) has declined by 21.2% (from $21.90 billion to $17.26 billion).
- The most recent figure is from TEVA PHARMACEUTICAL INDUSTRIES LTD’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: